TitleAssociate Professor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lee MS, Kaseb AO, Pant S, Lee MS, Kaseb AO, Pant S. The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers. Clin Cancer Res. 2023 09 01; 29(17):3267-3274. PMID: 37092904.
      Citations:    Fields:    Translation:Humans
    2. Nardo M, Yilmaz B, Nelson BE, Torres HA, Wang LS, Granwehr BP, Song J, Dalla Pria HRF, Trinh VA, Glitza Oliva IC, Patel SP, Tannir NM, Kaseb AO, Altan M, Lee SS, Miller E, Zhang H, Stephen BA, Naing A. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Viral Hepatitis: The MD Anderson Cancer Center Experience. Oncologist. 2023 08 03; 28(8):714-721. PMID: 36952233; PMCID: PMC10400154.
      Citations: 1     Fields:    Translation:Humans
    3. Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A, CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023 Jul 24. PMID: 37499670.
      Citations: 1     Fields:    
    4. Chamseddine S, Mohamed YI, Lee SS, Yao JC, Hu ZI, Tran Cao HS, Xiao L, Sun R, Morris JS, Hatia RI, Hassan M, Duda DG, Diab M, Mohamed A, Nassar A, Datar S, Amin HM, Kaseb AO. Clinical and Prognostic Biomarker Value of Blood Circulating Inflammatory Cytokines in Hepatocellular Carcinoma. Oncology. 2023 Jul 19. PMID: 37467732.
      Citations:    Fields:    
    5. Chamseddine S, LaPelusa M, Kaseb AO. Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review. Cancers (Basel). 2023 Jul 05; 15(13). PMID: 37444618; PMCID: PMC10340217.
    6. Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol. 2023 Sep 01; 118(9):1609-1617. PMID: 37307533.
      Citations:    Fields:    Translation:HumansCells
    7. George B, George SK, Shi W, Haque A, Shi P, Eskandari G, Axelson M, Larsson O, Kaseb AO, Amin HM. Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma. J Hematol Oncol. 2023 Jun 13; 16(1):61. PMID: 37312210; PMCID: PMC10265893.
      Citations:    Fields:    
    8. Lin YM, Fellman BM, Taiji R, Paolucci I, Silva JAM, Koay EJ, Avritscher R, Mahvash A, Holliday EB, Lee SS, Kaseb AO, Das P, Vauthey JN, Odisio BC. Salvage Locoregional Therapy Following Progression After Radiotherapy for Hepatocellular Carcinoma Is Associated with Improved Outcomes. J Gastrointest Surg. 2023 09; 27(9):1867-1875. PMID: 37268830.
      Citations:    Fields:    Translation:Humans
    9. Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang JY, Pandit SK, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. Proc Natl Acad Sci U S A. 2023 05 09; 120(19):e2300706120. PMID: 37126700; PMCID: PMC10175751.
      Citations:    Fields:    Translation:HumansCells
    10. El-Serag HB, Ward JW, Asrani SK, Singal AG, Rich N, Thrift AP, Deshpande S, Turner BJ, Kaseb AO, Harrison AC, Fortune BE, Kanwal F. Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference. Clin Gastroenterol Hepatol. 2023 Aug; 21(9):2183-2192. PMID: 37086825.
      Citations:    Fields:    
    11. Kothari AN, Massarweh NN, Flitcroft MA, Newhook T, Tzeng CD, Chun YS, Kaseb AO, Vauthey JN, Tran Cao HS. Evaluating the benefit of surgical resection for hepatocellular carcinoma with multifocality or intrahepatic vascular invasion. HPB (Oxford). 2023 Jul; 25(7):758-765. PMID: 37085394.
      Citations:    Fields:    Translation:Humans
    12. Gu L, Zhu Y, Lee M, Nguyen A, Ryujin NT, Huang J, Chamseddine S, Xiao L, Mohamed YI, Kaseb AO, Karin M, Shalapour S. Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. bioRxiv. 2023 Mar 06. PMID: 36945365; PMCID: PMC10028807.
    13. Wu YL, van Hyfte G, ?zbek U, Reincke M, Gampa A, Mohamed YI, Nishida N, Wietharn B, Amara S, Lee PC, Scheiner B, Balcar L, Pinter M, Vogel A, Weinmann A, Saeed A, Pillai A, Rimassa L, Naqash AR, Muzaffar M, Huang YH, Kaseb AO, Kudo M, Pinato DJ, Ang C. Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Front Oncol. 2023; 13:1128569. PMID: 36865801; PMCID: PMC9971987.
    14. Moawad AW, Morshid A, Khalaf AM, Elmohr MM, Hazle JD, Fuentes D, Badawy M, Kaseb AO, Hassan M, Mahvash A, Szklaruk J, Qayyum A, Abusaif A, Bennett WC, Nolan TS, Camp B, Elsayes KM. Multimodality annotated hepatocellular carcinoma data set including pre-?and post-TACE with imaging segmentation. Sci Data. 2023 01 18; 10(1):33. PMID: 36653372; PMCID: PMC9849450.
      Citations: 1     Fields:    Translation:Humans
    15. Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M, Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Mohamed YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Kudo M, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study. Liver Int. 2023 03; 43(3):695-707. PMID: 36577703.
      Citations:    Fields:    Translation:Humans
    16. Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 12 06; 13:1314-1321. PMID: 36473155; PMCID: PMC9726202.
      Citations: 1     Fields:    Translation:Humans
    17. Hsiehchen D, Bucheit L, Yang D, Beg MS, Lim M, Lee SS, Kasi PM, Kaseb AO, Zhu H. Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers. Nat Commun. 2022 Dec 03; 13(1):7477. PMID: 36463294; PMCID: PMC9719461.
      Citations:    Fields:    Translation:Humans
    18. Mohamed A, Azmi AS, Asa SL, Tirumani SH, Mahipal A, Cjakrabarti S, Bajor D, Selfridge JE, Kaseb AO. Thymoquinone Plus Immunotherapy in Extra-Pulmonary Neuroendocrine Carcinoma: Case Series for a Novel Combination. Curr Oncol. 2022 Nov 21; 29(11):9018-9030. PMID: 36421360; PMCID: PMC9689659.
      Citations:    Fields:    Translation:Humans
    19. Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y. Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2022; 9:1065-1079. PMID: 36254201; PMCID: PMC9569161.
      Citations: 2     
    20. Kaseb AO, Haque A, Vishwamitra D, Hassan MM, Xiao L, George B, Sahu V, Mohamed YI, Carmagnani Pestana R, Lombardo JL, Avritscher R, Yao JC, Wolff RA, Rashid A, Morris JS, Amin HM. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Front Oncol. 2022; 12:986305. PMID: 36276070; PMCID: PMC9582251.
      Citations: 1     
    21. Mu?oz NM, Dupuis C, Williams M, Dixon K, McWatters A, Zhang J, Pavuluri S, Rao A, Duda DG, Kaseb A, Sheth RA. Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis. Sci Rep. 2022 08 24; 12(1):14449. PMID: 36002545; PMCID: PMC9402568.
    22. Haque A, Sahu V, Lombardo JL, Xiao L, George B, Wolff RA, Morris JS, Rashid A, Kopchick JJ, Kaseb AO, Amin HM. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. J Hepatocell Carcinoma. 2022; 9:823-837. PMID: 35996397; PMCID: PMC9391993.
    23. Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T, Verset G, Merle P. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022 08; 23(8):995-1008. PMID: 35798016.
      Citations:    Fields:    
    24. Lee SH, Yim SY, Jeong YS, Li QX, Kang SH, Sohn BH, Kumar SV, Shin JH, Choi YR, Shim JJ, Kim H, Kim JH, Kim S, Guo S, Johnson RL, Kaseb A, Kang KJ, Chun YS, Jang HJ, Lee BG, Woo HG, Ha MJ, Akbani R, Roberts LR, Wheeler DA, Lee JS. Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes. Hepatology. 2022 12; 76(6):1634-1648. PMID: 35349735; PMCID: PMC9519807.
      Citations:    Fields:    
    25. Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022 08; 28(8):1599-1611. PMID: 35739268.
      Citations: 1     Fields:    
    26. Marinelli B, Kim E, D'Alessio A, Cedillo M, Sinha I, Debnath N, Kudo M, Nishida N, Saeed A, Hildebrand H, Kaseb AO, Abugabal YI, Pillai A, Huang YH, Khan U, Muzaffar M, Naqash AR, Patel R, Fischman A, Bishay V, Bettinger D, Sung M, Ang C, Schwartz M, Pinato DJ, Marron T. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022 06; 10(6). PMID: 35710293; PMCID: PMC9204420.
      Citations:    Fields:    Translation:Humans
    27. Bencheqroun H, Ahmed Y, Kocak M, Villa E, Barrera C, Mohiuddin M, Fortunet R, Iyoha E, Bates D, Okpalor C, Agbosasa O, Mohammed K, Pondell S, Mohamed A, Mohamed YI, Gok Yavuz B, Kaseb MO, Kasseb OO, Gocio MY, Tu PT, Li D, Lu J, Selim A, Ma Q, Kaseb AO. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of ThymoQuinone Formula (TQF) for Treating Outpatient SARS-CoV-2. Pathogens. 2022 May 07; 11(5). PMID: 35631072; PMCID: PMC9144779.
    28. Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun. 2022 07; 6(7):1776-1785. PMID: 35481940; PMCID: PMC9234627.
      Citations: 1     Fields:    Translation:Humans
    29. Manzar GS, De BS, Abana CO, Lee SS, Javle M, Kaseb AO, Vauthey JN, Tran Cao HS, Koong AC, Smith GL, Taniguchi CM, Holliday EB, Das P, Koay EJ, Ludmir EB. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers (Basel). 2022 Apr 09; 14(8). PMID: 35454808; PMCID: PMC9032898.
    30. Abdelrahim M, Esmail A, Al Saadi N, Zsigmond E, Al Najjar E, Bugazia D, Al-Rawi H, Alsaadi A, Kaseb AO. Thymoquinone's Antiviral Effects: It is Time to be Proven in the Covid-19 Pandemic Era and its Omicron Variant Surge. Front Pharmacol. 2022; 13:848676. PMID: 35462919; PMCID: PMC9022724.
    31. Abdelrahim M, Esmail A, Saharia A, Abudayyeh A, Abdel-Wahab N, Diab A, Murakami N, Kaseb AO, Chang JC, Gaber AO, Ghobrial RM. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View. Cancers (Basel). 2022 Mar 30; 14(7). PMID: 35406533; PMCID: PMC8997123.
      Citations: 5     
    32. Lithy RM, Elbaz T, H Abdelmaksoud A, M Nabil M, Rashed N, Omran D, Kaseb AO, O Abdelaziz A, I Shousha H. Survival and recurrence rates of hepatocellular carcinoma after treatment of chronic hepatitis C using direct acting antivirals. Eur J Gastroenterol Hepatol. 2022 02 01; 34(2):227-234. PMID: 33208688.
      Citations: 2     Fields:    Translation:Humans
    33. Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Singh Raghav KP, Rashid A, Carter K, Chun YS, Tzeng CD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218. PMID: 35065057; PMCID: PMC8840977.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    34. Lee SH, Jeong YS, Lee S, Sohn BH, Cheong JH, Jang HJ, Kaseb A, Roberts L, Yim SY, Chun YS, Lee JS, Hwang HK, Choi GH, Kang CM, Choi JS, Lee WJ. Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials. Cancer Commun (Lond). 2022 02; 42(2):179-183. PMID: 35032367; PMCID: PMC8822477.
      Citations:    Fields:    Translation:HumansCells
    35. Wang Z, Kaseb AO, Amin HM, Hassan MM, Wang W, Morris JS. Bayesian Edge Regression in Undirected Graphical Models to Characterize Interpatient Heterogeneity in Cancer. J Am Stat Assoc. 2022; 117(538):533-546. PMID: 36090952; PMCID: PMC9454401.
    36. Abdelsalam ME, Figueira TMA, Ensor J, Tam AL, Avritscher R, Kaseb A, Gupta S. The Impact of the Use of C-Arm Cone-Beam CT During Chemoembolization for Hepatocellular Carcinoma. Curr Med Imaging. 2022; 18(4):372-380. PMID: 34420509.
      Citations:    Fields:    Translation:Humans
    37. Muhammed A, Fulgenzi CAM, Dharmapuri S, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Saeed A, Hildebrand H, Muzaffar M, Navaid M, Naqash AR, Gampa A, Ozbek U, Lin JY, Perone Y, Vincenzi B, Silletta M, Pillai A, Wang Y, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Di Tommaso L, Kudo M, Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Ang C, Pinato DJ. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers (Basel). 2021 Dec 31; 14(1). PMID: 35008350; PMCID: PMC8750517.
    38. McMillan RR, Javle M, Kodali S, Saharia A, Mobley C, Heyne K, Hobeika MJ, Lunsford KE, Victor DW, Shetty A, McFadden RS, Abdelrahim M, Kaseb A, Divatia M, Yu N, Nolte Fong J, Moore LW, Nguyen DT, Graviss EA, Gaber AO, Vauthey JN, Ghobrial RM. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma. Am J Transplant. 2022 03; 22(3):823-832. PMID: 34856069.
      Citations: 4     Fields:    Translation:Humans
    39. Teyateeti A, Mahvash A, Long J, Abdelsalam M, Avritscher R, Kaseb A, Odisio B, Ravizzini G, Surasi D, Teyateeti A, Macapinlac H, Kappadath SC. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib. World J Gastroenterol. 2021 Dec 21; 27(47):8166-8181. PMID: 35068861; PMCID: PMC8704272.
      Citations:    Fields:    Translation:Humans
    40. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022 Apr; 76(4):862-873. PMID: 34902530.
      Citations: 17     Fields:    Translation:Humans
    41. Fessas P, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, Saeed A, Jun T, Dharmapuri S, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, Nishida N, Kudo M, Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Naqash AR, Sharon E, Cortellini A, Pinato DJ. Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. Liver Cancer. 2021 Nov; 10(6):583-592. PMID: 34950181; PMCID: PMC8647090.
      Citations: 2     
    42. Kaseb AO, Sperandio RC, Pestana RC, Miyamura BV. Hepatocellular Carcinoma Immunotherapy. Annu Rev Med. 2022 01 27; 73:267-278. PMID: 34606324.
      Citations: 3     Fields:    Translation:Humans
    43. Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1195-1207. PMID: 34595140; PMCID: PMC8478438.
      Citations: 3     
    44. Moussa I, Day RS, Li R, Kaseb A, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Association of dietary fat intake and hepatocellular carcinoma among US adults. Cancer Med. 2021 10; 10(20):7308-7319. PMID: 34535983; PMCID: PMC8525131.
      Citations: 1     Fields:    Translation:Humans
    45. Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1129-1145. PMID: 34527608; PMCID: PMC8437411.
      Citations: 1     
    46. Pinato DJ, Marron TU, Mishra-Kalyani PS, Gong Y, Wei G, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, D'Alessio A, Kaseb AO, Huang YH, Ang C, Schneider J, Pillai A, Rimassa L, Goldberg KB, Pazdur R, Theoret M, Lemery S, Fashoyin-Aje ', Cortellini A, Pelosof L. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer. 2021 11; 157:140-152. PMID: 34508996.
      Citations: 6     Fields:    Translation:Humans
    47. Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Sangro B, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer. 2021 09; 9(9). PMID: 34518290; PMCID: PMC8438858.
      Citations: 4     Fields:    Translation:Humans
    48. Zheng J, Daniel CR, Hatia RI, Stuff J, Abdelhakeem AA, Rashid A, Chun YS, Jalal PK, Kaseb AO, Li D, Hassan MM. Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A USA-Based Study. Hepatology. 2021 12; 74(6):3161-3173. PMID: 34233041; PMCID: PMC8639645.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    49. Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol. 2021; 13:17588359211031141. PMID: 34377156; PMCID: PMC8327224.
    50. Chang KY, Chiang NJ, Wu SY, Yen CJ, Chen SH, Yeh YM, Li CF, Feng X, Wu K, Johnston A, Bomalaski JS, Wu BW, Gao J, Subudhi SK, Kaseb AO, Blando JM, Yadav SS, Szlosarek PW, Chen LT. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. Oncoimmunology. 2021; 10(1):1943253. PMID: 34290906; PMCID: PMC8276661.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    51. Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, Haque A, Abdel-Wahab R, Mohamed YI, Ballard KL, Wolff RA, George B, Li L, Allen G, Weylandt M, Li D, Wang W, Raghav K, Yao J, Amin HM, Kaseb AO. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology. 2021 06; 73(6):2278-2292. PMID: 32931023; PMCID: PMC7956911.
      Citations: 1     Fields:    Translation:Humans
    52. Moussa I, Day RS, Li R, Du XL, Kaseb AO, Jalal PK, Daniel-MacDougall C, Hatia RI, Abdelhakeem A, Rashid A, Chun YS, Li D, Hassan MM. Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults. Nutrients. 2021 Jun 11; 13(6). PMID: 34208122; PMCID: PMC8230753.
      Citations: 5     Fields:    Translation:HumansAnimals
    53. Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M, Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 07; 22(7):991-1001. PMID: 34051880.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    54. Morris JS, Hassan M, Amin H, Kaseb A. REPLY. Hepatology. 2021 06; 73(6):2612. PMID: 33170975.
      Citations:    Fields:    
    55. Morris JS, Hassan M, Amin H, Kaseb A. REPLY. Hepatology. 2021 06; 73(6):2614. PMID: 33171542.
      Citations:    Fields:    
    56. Mohamed YI, Lee S, Xiao L, Hassan MM, Qayyum A, Hiatia R, Pestana RC, Haque A, George B, Rashid A, Duda DG, Elghazaly H, Wolff RA, Morris JS, Yao J, Amin HM, Kaseb AO. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget. 2021 Apr 13; 12(8):756-766. PMID: 33889299; PMCID: PMC8057275.
      Citations: 1     Fields:    
    57. Pfister D, Govaere O, Pinter M, Szydlowska M, Deczkowska A, Weiner A, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Inverso D, Singh I, Teijeiro A, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Allison M, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Finkelmeier F, Waidmann O, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, De Dosso S, Mallm JP, Umansky V, Jugold M, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Kikuchi H, Duda DG, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Anstee QM, Amit I, Knolle P, Becher B, Heikenwalder M, N??ez NG, Pinyol R, Gupta R, Qiu M, M?ller F, Yousuf S, Castet F, Montironi C, Schattenberg JM, Bugianesi E, Ratziu V, Peck-Radosavljevic M, Hucke F, Trojan J, R?ssler F, Siebenh?ner A, Luedde T, M?ller-Stich B, K?tting F, Malek N, Spahn S, Bitzer M, Wolter K, Zender L, Marche PN, Decaens T, Roth S, Jilkova ZM, Claassen M, Llovet JM. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021 04; 592(7854):450-456. PMID: 33762733; PMCID: PMC8046670.
      Citations: 118     Fields:    Translation:HumansAnimalsCells
    58. Kaseb AO, Mohamed YI, Malek AE, Raad II, Altameemi L, Li D, Kaseb OA, Kaseb SA, Selim A, Ma Q. The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression on the Incidence and Severity of COVID-19 Infection. Pathogens. 2021 Mar 22; 10(3). PMID: 33809851; PMCID: PMC8004186.
      Citations: 7     
    59. Yao S, Janku F, Subbiah V, Stewart J, Patel SP, Kaseb A, Westin SN, Naing A, Tsimberidou AM, Hong D, Piha-Paul SA, Shi N, Johnston A, Bomalaski J, Fu S. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer. 2021 04; 124(9):1533-1539. PMID: 33674736; PMCID: PMC8076217.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    60. De B, Ng SP, Liu AY, Avila S, Tao R, Holliday EB, Brownlee Z, Kaseb A, Lee S, Raghav K, Vauthey JN, Minsky BD, Herman JM, Das P, Smith GL, Taniguchi CM, Krishnan S, Crane CH, Grassberger C, Hong TS, Lin SH, Koong AC, Mohan R, Koay EJ. Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma. 2021; 8:57-69. PMID: 33688489; PMCID: PMC7937383.
      Citations: 9     
    61. Lee RT, Yang P, Alahmadi A, McQuade J, Yuan E, Difeo A, Narla G, Kaseb A. Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series. Case Rep Oncol. 2021 Jan-Apr; 14(1):224-231. PMID: 33776708; PMCID: PMC7983630.
      Citations: 1     
    62. Demir T, Lee SS, Kaseb AO. Systemic therapy of liver cancer. Adv Cancer Res. 2021; 149:257-294. PMID: 33579425.
      Citations: 10     Fields:    Translation:HumansAnimals
    63. Sahin IH, Khalil L, Millett R, Kaseb A. Neoadjuvant and adjuvant treatment approaches for hepatocellular carcinoma: future outlook. Chin Clin Oncol. 2021 Feb; 10(1):7. PMID: 33440948.
      Citations: 2     Fields:    Translation:Humans
    64. Hui D, Puac V, Shelal Z, Liu D, Maddi R, Kaseb A, Javle M, Overman M, Yennurajalingam S, Gallagher C, Bruera E. Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. J Pain Symptom Manage. 2021 08; 62(2):223-232.e1. PMID: 33388382.
      Citations:    Fields:    Translation:Humans
    65. Dupuis C, Williams M, Dixon K, McWatters A, Avritscher R, Bouchard R, Kaseb A, Schachtschneider KM, Rao A, Sheth RA, Mu?oz NM. Molecularly targeted photothermal ablation improves tumor specificity and immune modulation in a rat model of hepatocellular carcinoma. Commun Biol. 2020 12 17; 3(1):783. PMID: 33335270; PMCID: PMC7746712.
      Citations: 6     Translation:Animals
    66. Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. J Clin Oncol. 2020 12 20; 38(36):4317-4345. PMID: 33197225.
      Citations: 86     Fields:    Translation:HumansCTClinical Trials
    67. Abdel-Wahab R, Hassan MM, George B, Carmagnani Pestana R, Xiao L, Lacin S, Yalcin S, Shalaby AS, Al-Shamsi HO, Raghav K, Wolff RA, Yao JC, Girard L, Haque A, Duda DG, Dima S, Popescu I, Elghazaly HA, Vauthey JN, Aloia TA, Tzeng CW, Chun YS, Rashid A, Morris JS, Amin HM, Kaseb AO. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846. PMID: 33027788; PMCID: PMC7704605.
      Citations: 2     Fields:    Translation:Humans
    68. Pinato DJ, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Fessas P, Nimkar N, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Lozano-Kuehne J, Rimassa L, Ang C, Marron TU, Bettinger D. Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy. J Immunother Cancer. 2020 10; 8(2). PMID: 33028690; PMCID: PMC7542664.
      Citations: 6     Fields:    Translation:Humans
    69. Ismail MS, Hassan M, Khaderi SA, Yousry WA, Kamal El-Din MM, Bahaa El-Din MM, El Sayed OA, Kaseb AO, Goss JA, Kanwal F, Jalal PK. Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma. World J Hepatol. 2020 Sep 27; 12(9):628-640. PMID: 33033569; PMCID: PMC7522560.
      Citations: 1     
    70. Qayyum A, Bhosale P, Aslam R, Avritscher R, Ma J, Pagel MD, Sun J, Mohamed Y, Rashid A, Beretta L, Kaseb AO. Effect of sarcopenia on systemic targeted therapy response in patients with advanced hepatocellular carcinoma. Abdom Radiol (NY). 2021 03; 46(3):1008-1015. PMID: 32974761; PMCID: PMC8191337.
      Citations: 4     Fields:    Translation:Humans
    71. Lacin S, Yalcin S, Karakas Y, Hassan MM, Amin H, Mohamed YI, Rashid A, Morris JS, Xiao L, Qayyum A, Kaseb AO. Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study. J Hepatocell Carcinoma. 2020; 7:143-153. PMID: 32984091; PMCID: PMC7502406.
      Citations: 1     
    72. Teyateeti A, Mahvash A, Long JP, Abdelsalam ME, Avritscher R, Chasen B, Kaseb AO, Kuban JD, Murthy R, Odisio BC, Teyateeti A, Macapinlac HA, Kappadath SC. Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients. J Hepatocell Carcinoma. 2020; 7:117-131. PMID: 32984089; PMCID: PMC7500841.
      Citations: 4     
    73. Thomas MA, Mahvash A, Abdelsalam M, Kaseb AO, Kappadath SC. Planning dosimetry for 90 Y radioembolization with glass microspheres: Evaluating the fidelity of 99m Tc-MAA and partition model predictions. Med Phys. 2020 Oct; 47(10):5333-5342. PMID: 32790882.
      Citations: 4     Fields:    Translation:Humans
    74. Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Rafeh Naqash A, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Benevento F, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Rimassa L, Ang C, Marron T, Pinato DJ. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer. 2020 08; 8(2). PMID: 32868393; PMCID: PMC7462152.
      Citations: 11     Fields:    Translation:Humans
    75. Angelidakis G, Krishnan S, Cabrera NL, Jiang Y, Pushparaji B, Kaseb A, Torres HA. Virologic Impact of Radiotherapy in Hepatitis C Virus-Infected Patients With Hepatocellular Carcinoma. Hepatology. 2020 08; 72(2):775-777. PMID: 31944343.
      Citations: 1     Fields:    Translation:HumansCells
    76. Pinato DJ, Kaneko T, Saeed A, Pressiani T, Kaseb A, Wang Y, Szafron D, Jun T, Dharmapuri S, Naqash AR, Muzaffar M, Navaid M, Lee CJ, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Ang C, Marron TU, Khan U, Personeni N, Rimassa L, Huang YH. Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade. Cancers (Basel). 2020 Jul 10; 12(7). PMID: 32664319; PMCID: PMC7408648.
      Citations: 11     
    77. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL, IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020 05 14; 382(20):1894-1905. PMID: 32402160.
      Citations: 1030     Fields:    Translation:HumansCTClinical Trials
    78. Shi D, Shi Y, Kaseb AO, Qi X, Zhang Y, Chi J, Lu Q, Gao H, Jiang H, Wang H, Yuan D, Ma H, Wang H, Li Z, Zhai B. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials. Clin Cancer Res. 2020 08 01; 26(15):3979-3989. PMID: 32371538.
      Citations: 51     Fields:    Translation:HumansCells
    79. Gjyshi O, Boyce-Fappiano D, Pezzi TA, Ludmir EB, Xiao L, Kaseb A, Amini B, Yeboa DN, Bishop AJ, Li J, Rhines LD, Tatsui CE, Briere TM, Ghia AJ. Spine stereotactic radiosurgery for metastases from hepatobiliary malignancies: patient selection using PRISM scoring. J Neurooncol. 2020 Jun; 148(2):327-334. PMID: 32358642.
      Citations: 1     Fields:    Translation:Humans
    80. Hack SP, Spahn J, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncol. 2020 May; 16(15):975-989. PMID: 32352320.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    81. Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma. 2020; 7:77-89. PMID: 32426302; PMCID: PMC7188073.
      Citations: 13     
    82. Torres HA, Lok AS, Suarez-Almazor ME, Warneke CL, Kaseb A, Miller E, Sturgis EM, Foreman JT, Angelidakis G, Ahmed S, Ferrajoli A, Samaniego F, Hawk ET, Hwang JP. Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. Support Care Cancer. 2021 Jan; 29(1):97-105. PMID: 32314052; PMCID: PMC9706509.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    83. Yavuz BG, Pestana RC, Abugabal YI, Krishnan S, Chen J, Hassan MM, Wolff RA, Rashid A, Amin HM, Kaseb AO. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget. 2020 Mar 31; 11(13):1186-1201. PMID: 32284794; PMCID: PMC7138168.
      Citations: 9     Fields:    
    84. Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931. PMID: 31852833; PMCID: PMC7771658.
      Citations: 17     Fields:    Translation:Humans
    85. Qayyum A, Hwang KP, Stafford J, Verma A, Maru DM, Sandesh S, Sun J, Pestana RC, Avritscher R, Hassan MM, Amin H, Rashid A, Wistuba II, Ehman RL, Ma J, Kaseb AO. Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC. J Immunother Cancer. 2019 11 28; 7(1):329. PMID: 31779702; PMCID: PMC6883599.
      Citations: 12     Fields:    Translation:HumansCells
    86. El Kassas M, Tawheed A, Eltabbakh M, Kaseb A. Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves. J Hepatocell Carcinoma. 2019; 6:183-191. PMID: 31819865; PMCID: PMC6879003.
      Citations: 4     
    87. Avritscher R, Jo N, Polak U, Cortes AC, Nishiofuku H, Odisio BC, Takaki H, Tam AL, Melancon MP, Yevich S, Qayyum A, Kaseb A, Kichikawa K, Gupta S, Goldberg SN, Chang SH. Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2020 Feb; 43(2):311-321. PMID: 31591689.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    88. Morshid A, Elsayes KM, Khalaf AM, Elmohr MM, Yu J, Kaseb AO, Hassan M, Mahvash A, Wang Z, Hazle JD, Fuentes D. A machine learning model to predict hepatocellular carcinoma response to transcatheter arterial chemoembolization. Radiol Artif Intell. 2019 Sep; 1(5). PMID: 31858078; PMCID: PMC6920060.
      Citations: 26     
    89. Kahle MP, Bailey AM, Wathoo C, Balaji K, Demirhan ME, Yang D, Javle M, Kaseb A, Eng C, Subbiah V, Janku F, Raymond VM, Lanman RB, Mills Shaw KR, Meric-Bernstam F, S?nchez NS. Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. JCO Precis Oncol. 2019; 3. PMID: 32923868; PMCID: PMC7448805.
      Citations: 3     Fields:    
    90. Okuno M, Newhook TE, Joechle K, Kawaguchi Y, De Bellis M, Tzeng CD, Chun YS, Aloia TA, Shindoh J, Kaseb AO, Vauthey JN. Characteristics of atypical large well-differentiated hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma? HPB (Oxford). 2020 04; 22(4):545-552. PMID: 31533893.
      Citations: 2     Fields:    Translation:Humans
    91. Kaseb AO, Sen S, Kelley RK, Tan B, Bocobo AG, Lim KH, Abdel-Wahab R, Uemura M, Pestana RC, Qiao W, Xiao L, Morris J, Amin HM, Hassan MM, Rashid A, Banks KC, Lanman RB, Talasaz A, Mills-Shaw KR, George B, Haque A, Raghav KPS, Wolff RA, Yao JC, Meric-Bernstam F, Ikeda S, Kurzrock R, S?nchez NS. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118. PMID: 31363003; PMCID: PMC9292132.
      Citations: 27     Fields:    Translation:Humans
    92. George B, George SK, Shi W, Haque A, Shi P, Eskandari G, Axelson M, Larsson O, Kaseb AO, Amin HM. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma. J Hematol Oncol. 2019 07 24; 12(1):80. PMID: 31340850; PMCID: PMC6657048.
      Citations: 8     Fields:    Translation:Humans
    93. Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019 07 15; 129(8):3324-3338. PMID: 31305264; PMCID: PMC6668668.
      Citations: 90     Fields:    Translation:HumansAnimalsCells
    94. Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey JN, Allison JP, Sharma P. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma. Cancer Immunol Res. 2019 Sep; 7(9):1390-1395. PMID: 31289040; PMCID: PMC7726707.
      Citations: 17     Fields:    Translation:HumansCells
    95. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, Raghav KPS, Iwasaki M, Masci P, Ramanathan RK, Ahn DH, Bekaii-Saab TS, Borad MJ. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):824-830. PMID: 30998813; PMCID: PMC6567834.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    96. Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM. Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study. J Comput Assist Tomogr. 2019 May/Jun; 43(3):499-506. PMID: 31082956.
      Citations: 1     Fields:    Translation:Humans
    97. El Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues - A mini-review. J Adv Res. 2019 May; 17:43-48. PMID: 31193326; PMCID: PMC6526204.
      Citations: 5     Fields:    
    98. Torres HA, Economides MP, Angelidakis G, Hosry J, Kyvernitakis A, Mahale P, Jiang Y, Miller E, Blechacz B, Naing A, Samaniego F, Kaseb A, Raad II, Granwehr BP. Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. Am J Gastroenterol. 2019 02; 114(2):250-257. PMID: 30410039.
      Citations: 5     Fields:    Translation:Humans
    99. Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol. 2019 04; 133:54-61. PMID: 30935582; PMCID: PMC6446916.
      Citations: 17     Fields:    Translation:Humans
    100. Pestana RC, Hassan MM, Abdel-Wahab R, Abugabal YI, Girard LM, Li D, Chang P, Raghav K, Morris J, Wolff RA, Rashid A, Amin HM, Kaseb A. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget. 2018 Dec 28; 9(102):37721-37732. PMID: 30701027; PMCID: PMC6340869.
      Citations: 7     Fields:    
    101. Ganeshan D, Szklaruk J, Kaseb A, Kattan A, Elsayes KM. Fibrolamellar hepatocellular carcinoma: multiphasic CT features of the primary tumor on pre-therapy CT and pattern of distant metastases. Abdom Radiol (NY). 2018 12; 43(12):3340-3348. PMID: 29948061.
      Citations: 3     Fields:    Translation:Humans
    102. Jain A, Borad MJ, Kelley RK, Wang Y, Abdel-Wahab R, Meric-Bernstam F, Baggerly KA, Kaseb AO, Al-Shamsi HO, Ahn DH, DeLeon T, Bocobo AG, Bekaii-Saab T, Shroff RT, Javle M. Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype. JCO Precis Oncol. 2018 Nov; 2:1-12. PMID: 35135097.
      Citations: 8     Fields:    
    103. Hosry J, Angelidakis G, Kaseb A, Jiang Y, Torres HA. Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study. Clin Infect Dis. 2018 10 30; 67(10):1635-1636. PMID: 30124786; PMCID: PMC6206115.
      Citations:    Fields:    Translation:HumansCells
    104. Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, Raghav K, Kaseb A, Aloia TA, Vauthey JN, Tzeng CD, Herman JM, Koong AC, Krishnan SX, Minsky BD, Crane CH, Das P, Koay EJ. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892. PMID: 30152073; PMCID: PMC6198206.
      Citations: 9     Fields:    Translation:Humans
    105. Dandachi D, Hassan M, Kaseb A, Angelidakis G, Torres HA. Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer. J Hepatocell Carcinoma. 2018; 5:81-86. PMID: 30123783; PMCID: PMC6080868.
      Citations: 3     
    106. Khalaf AM, Fuentes D, Morshid AI, Burke MR, Kaseb AO, Hassan M, Hazle JD, Elsayes KM. Role of Wnt/?-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance. J Hepatocell Carcinoma. 2018; 5:61-73. PMID: 29984212; PMCID: PMC6027703.
      Citations: 62     
    107. Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-SPECT/CT-Based Voxel Dosimetry. Int J Radiat Oncol Biol Phys. 2018 10 01; 102(2):451-461. PMID: 30191875.
      Citations: 25     Fields:    Translation:Humans
    108. Kaseb AO. Editorial: charting the future of hepatocellular carcinoma publications. J Hepatocell Carcinoma. 2018; 5:51-54. PMID: 29774205; PMCID: PMC5947843.
    109. Niekamp A, Abdel-Wahab R, Kuban J, Odisio BC, Mahvash A, Hassan MM, Qayyum A, Kaseb A, Sheth RA. Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma. J Clin Med. 2018 Apr 14; 7(4). PMID: 29661994; PMCID: PMC5920457.
      Citations: 5     
    110. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N, Mobley CM, Saharia A, Victor DW, Nguyen DT, Graviss EA, Kaseb AO, McFadden RS, Aloia TA, Conrad C, Li XC, Monsour HP, Gaber AO, Vauthey JN, Ghobrial RM, Methodist?MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC). Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018 05; 3(5):337-348. PMID: 29548617.
      Citations: 47     Fields:    Translation:Humans
    111. Gingold JA, Zhu D, Lee DF, Kaseb A, Chen J. Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends Mol Med. 2018 04; 24(4):395-411. PMID: 29530485.
      Citations: 23     Fields:    Translation:HumansAnimals
    112. Kaseb AO. Grant, deny, or reassess the role of yttrium-90 in hepatocellular carcinoma? Lancet Oncol. 2017 12; 18(12):1560-1561. PMID: 29107680.
      Citations:    Fields:    Translation:Humans
    113. Odisio BC, Kaseb AO. Anti-angiogenic therapy in the setting of TACE: an elusive synergy? Lancet Gastroenterol Hepatol. 2018 01; 3(1):5-6. PMID: 28988686.
      Citations: 1     Fields:    Translation:Humans
    114. Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, Kaseb AO, Cohen L, Bruera E. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J Natl Compr Canc Netw. 2017 09; 15(9):1111-1120. PMID: 28874596.
      Citations: 19     Fields:    Translation:HumansAnimals
    115. Torres HA, Shigle TL, Hammoudi N, Link JT, Samaniego F, Kaseb A, Mallet V. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017 Sep; 67(5):411-431. PMID: 28683174; PMCID: PMC5591069.
      Citations: 24     Fields:    Translation:Humans
    116. Al-Shamsi HO, Abdel-Wahab R, Hassan MM, Shalaby AS, Dahbour I, Lacin S, Mahvash A, Odisio BC, Murthy R, Avritscher R, Abdelsalam ME, Rashid A, Vauthey JN, Aloia TA, Conrad C, Chun YS, Krishnan S, Das P, Koay EJ, Amin HM, Yao JC, Kaseb AO. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4):233-242. PMID: 28683459; PMCID: PMC6743737.
      Citations: 1     Fields:    Translation:Humans
    117. Holliday EB, Tao R, Brownlee Z, Das P, Krishnan S, Taniguchi C, Minsky BD, Herman JM, Kaseb A, Raghav K, Conrad C, Vauthey JN, Aloia TA, Chun YS, Crane CH, Koay EJ. Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Clin Transl Radiat Oncol. 2017 Jun; 4:39-45. PMID: 29594206; PMCID: PMC5833919.
      Citations: 7     
    118. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799. PMID: 28579181; PMCID: PMC5901750.
      Citations: 33     Fields:    Translation:Humans
    119. Rogers JE, Bolonesi RM, Rashid A, Elsayes KM, Elbanan MG, Law L, Kaseb A, Shroff RT. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastrointest Oncol. 2017 Apr; 8(2):347-351. PMID: 28480073; PMCID: PMC5401851.
      Citations: 13     
    120. Ali MA, Lacin S, Abdel-Wahab R, Uemura M, Hassan M, Rashid A, Duda DG, Kaseb AO. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway? Onco Targets Ther. 2017; 10:1403-1412. PMID: 28424556; PMCID: PMC5344425.
      Citations: 4     
    121. Kutlu OC, Chan JA, Aloia TA, Chun YS, Kaseb AO, Passot G, Yamashita S, Vauthey JN, Conrad C. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. Cancer. 2017 05 15; 123(10):1817-1827. PMID: 28085184.
      Citations: 29     Fields:    Translation:Humans
    122. Vishwamitra D, George SK, Shi P, Kaseb AO, Amin HM. Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget. 2017 Jan 03; 8(1):1814-1844. PMID: 27661006; PMCID: PMC5352101.
      Citations: 18     Fields:    Translation:HumansCells
    123. Yamashita S, Koay EJ, Passot G, Shroff R, Raghav KP, Conrad C, Chun YS, Aloia TA, Tao R, Kaseb A, Javle M, Crane CH, Vauthey JN. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer. 2017 04 15; 123(8):1354-1362. PMID: 27984655; PMCID: PMC5384875.
      Citations: 17     Fields:    Translation:Humans
    124. Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. Eur J Nucl Med Mol Imaging. 2017 Jun; 44(6):969-978. PMID: 27942837; PMCID: PMC5400685.
      Citations: 5     Fields:    Translation:HumansCells
    125. Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, Wolff RA, Yao J, Rashid A, Vennapusa B, Feng J, Ohtomo T. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016 Oct 25; 7(43):69916-69926. PMID: 27655712; PMCID: PMC5342524.
      Citations: 23     Fields:    Translation:Humans
    126. Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531. PMID: 27589687; PMCID: PMC5341894.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    127. Abdelsalam ME, Murthy R, Avritscher R, Mahvash A, Wallace MJ, Kaseb AO, Odisio BC. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 3:55-61. PMID: 27785450; PMCID: PMC5067062.
      Citations: 3     
    128. Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, Ahn D, Bocobo AG, Zuo M, Kaseb A, Miller V, Stephens PJ, Meric-Bernstam F, Shroff R, Ross J. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 2016 Dec 15; 122(24):3838-3847. PMID: 27622582.
      Citations: 108     Fields:    Translation:HumansCells
    129. Yamashita S, Vauthey JN, Kaseb AO, Aloia TA, Conrad C, Hassan MM, Passot G, Raghav KP, Shama MA, Chun YS. Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. J Gastrointest Surg. 2016 10; 20(10):1725-31. PMID: 27456016.
      Citations: 12     Fields:    Translation:Humans
    130. Mitchell J, Tinkey PT, Avritscher R, Van Pelt C, Eskandari G, Konnath George S, Xiao L, Cressman E, Morris JS, Rashid A, Kaseb AO, Amin HM, Uthamanthil R. Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. Oncology. 2016; 91(2):90-100. PMID: 27305144; PMCID: PMC5432216.
      Citations: 10     Fields:    Translation:Animals
    131. Atta MM, Atta HM, Gad MA, Rashed LA, Said EM, Hassanien Sel-S, Kaseb AO. Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients. J Hepatocell Carcinoma. 2016; 3:19-24. PMID: 27574588; PMCID: PMC4994801.
      Citations: 5     
    132. Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. J Hepatol. 2016 10; 65(4):862-864. PMID: 27255582.
      Citations: 24     Fields:    Translation:Humans
    133. Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016; 9:773-80. PMID: 26929648; PMCID: PMC4760665.
      Citations: 10     
    134. Mahvash A, Murthy R, Odisio BC, Raghav KP, Girard L, Cheung S, Nguyen V, Ensor J, Gadani S, Elsayes KM, Abdel-Wahab R, Hassan M, Shalaby AS, Yao JC, Wallace MJ, Kaseb AO. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2016; 3:1-7. PMID: 27574586; PMCID: PMC4994795.
      Citations: 11     
    135. Tao R, Krishnan S, Bhosale PR, Javle MM, Aloia TA, Shroff RT, Kaseb AO, Bishop AJ, Swanick CW, Koay EJ, Thames HD, Hong TS, Das P, Crane CH. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016 Jan 20; 34(3):219-26. PMID: 26503201; PMCID: PMC4980564.
      Citations: 77     Fields:    Translation:Humans
    136. Sohn BH, Shim JJ, Kim SB, Jang KY, Kim SM, Kim JH, Hwang JE, Jang HJ, Lee HS, Kim SC, Jeong W, Kim SS, Park ES, Heo J, Kim YJ, Kim DG, Leem SH, Kaseb A, Hassan MM, Cha M, Chu IS, Johnson RL, Park YY, Lee JS. Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma. Clin Cancer Res. 2016 Mar 01; 22(5):1256-64. PMID: 26459179; PMCID: PMC5536176.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    137. Hassan MM, Abdel-Wahab R, Li D, Kaseb AO. Reply: To PMID 25836985. Gastroenterology. 2015 Nov; 149(6):1643-4. PMID: 26433110.
      Citations:    Fields:    Translation:Humans
    138. Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62. PMID: 26164085; PMCID: PMC4695071.
      Citations: 4     Fields:    Translation:Humans
    139. Jauch SF, Morris VK, Jensen CT, Kaseb AO. Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas: A case report. Pancreatology. 2016 Jan-Feb; 16(1):153-6. PMID: 26456669.
      Citations: 4     Fields:    Translation:Humans
    140. Abdel-Wahab R, Shehata S, Hassan MM, Habra MA, Eskandari G, Tinkey PT, Mitchell J, Lee JS, Amin HM, Kaseb AO. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma. 2015; 2:131-42. PMID: 27508202; PMCID: PMC4918293.
      Citations: 7     
    141. Abdel-Wahab R, Shehata S, Hassan MM, Xiao L, Lee JS, Cheung S, Essa HH, Hassabo HM, Shalaby AS, Mosad E, Raghav K, Rashid A, Wolff RA, Morris JS, Amin HM, Kaseb AO. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget. 2015 Aug 28; 6(25):21193-207. PMID: 26098859; PMCID: PMC4673259.
      Citations: 7     Fields:    Translation:Humans
    142. Bupathi M, Kaseb A, Meric-Bernstam F, Naing A. Hepatocellular carcinoma: Where there is unmet need. Mol Oncol. 2015 Oct; 9(8):1501-9. PMID: 26160430; PMCID: PMC5528787.
      Citations: 37     Fields:    Translation:HumansCells
    143. Odisio BC, Ashton A, Yan Y, Wei W, Kaseb A, Wallace MJ, Vauthey JN, Gupta S, Tam AL. Transarterial hepatic chemoembolization with 70-150 ?m drug-eluting beads: assessment of clinical safety and liver toxicity profile. J Vasc Interv Radiol. 2015 Jul; 26(7):965-71. PMID: 25979305; PMCID: PMC4484796.
      Citations: 12     Fields:    Translation:Humans
    144. Mohamed A, Chenna A, Abdelfatah M, Sanjay J, Mohammad MK, Saber I, Kauh J, Elhammali B, Kaseb A. Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma. J Gastrointest Cancer. 2015 Jun; 46(2):104-8. PMID: 25645584.
      Citations:    Fields:    Translation:HumansCells
    145. Javle M, Churi C, Kang HC, Shroff R, Janku F, Surapaneni R, Zuo M, Barrera C, Alshamsi H, Krishnan S, Mishra L, Wolff RA, Kaseb AO, Thomas MB, Siegel AB. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015 May 29; 8:58. PMID: 26022204; PMCID: PMC4469402.
      Citations: 77     Fields:    Translation:Humans
    146. Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, Hawk E, Morris J, Singh Raghav KP, Lee JS, Vauthey JN, Bortus G, Torres HA, Amos CI, Wolff RA, Li D. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. 2015 Jul; 149(1):119-29. PMID: 25836985; PMCID: PMC4778392.
      Citations: 38     Fields:    Translation:Humans
    147. Vishwamitra D, Curry CV, Alkan S, Song YH, Gallick GE, Kaseb AO, Shi P, Amin HM. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK? T-cell lymphoma. Mol Cancer. 2015 Feb 25; 14:53. PMID: 25884514; PMCID: PMC4415347.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    148. Kaseb AO. Welcome to Journal of Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2015; 2:1-2. PMID: 27508188; PMCID: PMC4918292.
    149. Torres HA, Mahale P, Blechacz B, Miller E, Kaseb A, Herlong HF, Fowler N, Jiang Y, Raad II, Kontoyiannis DP. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Canc Netw. 2015 Jan; 13(1):41-50. PMID: 25583768.
      Citations: 11     Fields:    Translation:HumansCells
    150. Kim JH, Sohn BH, Lee HS, Kim SB, Yoo JE, Park YY, Jeong W, Lee SS, Park ES, Kaseb A, Kim BH, Kim WB, Yeon JE, Byun KS, Chu IS, Kim SS, Wang XW, Thorgeirsson SS, Luk JM, Kang KJ, Heo J, Park YN, Lee JS. Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med. 2014 Dec; 11(12):e1001770. PMID: 25536056; PMCID: PMC4275163.
      Citations: 60     Fields:    Translation:Humans
    151. Mahale P, Kaseb AO, Hassan MM, Torres HA. Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection. Dig Liver Dis. 2015 Apr; 47(4):348-9. PMID: 25563811.
      Citations: 3     Fields:    Translation:HumansCells
    152. Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT. Second-line systemic treatment for advanced cholangiocarcinoma. J Gastrointest Oncol. 2014 Dec; 5(6):408-13. PMID: 25436118; PMCID: PMC4226829.
      Citations: 20     
    153. Bupathi M, Kaseb A, Janku F. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives. Onco Targets Ther. 2014; 7:1927-32. PMID: 25364263; PMCID: PMC4211614.
      Citations: 12     
    154. Faria SC, Szklaruk J, Kaseb AO, Hassabo HM, Elsayes KM. TNM/Okuda/Barcelona/UNOS/CLIP International Multidisciplinary Classification of Hepatocellular Carcinoma: concepts, perspectives, and radiologic implications. Abdom Imaging. 2014 Oct; 39(5):1070-87. PMID: 24695938.
      Citations: 16     Fields:    Translation:Humans
    155. Torres HA, Kaseb A, Mahale P, Miller E, Frenette C. Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series. J Hepatocell Carcinoma. 2014; 1:109-14. PMID: 27508180; PMCID: PMC4918269.
      Citations: 2     
    156. Janku F, Kaseb AO, Tsimberidou AM, Wolff RA, Kurzrock R. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. 2014 May 30; 5(10):3012-22. PMID: 24931142; PMCID: PMC4102787.
      Citations: 48     Fields:    Translation:HumansCells
    157. Kaseb AO, Xiao L, Hassan MM, Chae YK, Lee JS, Vauthey JN, Krishnan S, Cheung S, Hassabo HM, Aloia T, Conrad C, Curley SA, Vierling JM, Jalal P, Raghav K, Wallace M, Rashid A, Abbruzzese JL, Wolff RA, Morris JS. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst. 2014 May 09; 106(5). PMID: 24815863; PMCID: PMC4085880.
      Citations: 15     Fields:    Translation:Humans
    158. Ganeshan D, Szklaruk J, Kundra V, Kaseb A, Rashid A, Elsayes KM, Elsayes K. Imaging features of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol. 2014 Mar; 202(3):544-52. PMID: 24555590.
      Citations: 25     Fields:    Translation:Humans
    159. Kaseb AO, Shah NN, Hassabo HM, Morris JS, Xiao L, Abaza YM, Soliman K, Lee JS, Vauthey JN, Wallace M, Aloia TA, Curley S, Abbruzzese JL, Hassan MM. Reassessing hepatocellular carcinoma staging in a changing patient population. Oncology. 2014; 86(2):63-71. PMID: 24401634; PMCID: PMC4060614.
      Citations: 1     Fields:    Translation:Humans
    160. Zekri Ael-R, Nassar AA, El-Din El-Rouby MN, Shousha HI, Barakat AB, El-Desouky ED, Zayed NA, Ahmed OS, El-Din Youssef AS, Kaseb AO, Abd El-Aziz AO, Bahnassy AA. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pac J Cancer Prev. 2014 Jan; 14(11):6721-6. PMID: 24377595.
      Citations: 8     Fields:    Translation:HumansCells
    161. Asham EH, Kaseb A, Ghobrial RM. Management of hepatocellular carcinoma. Surg Clin North Am. 2013 Dec; 93(6):1423-50. PMID: 24206860.
      Citations: 21     Fields:    Translation:HumansCells
    162. Kaseb AO, Shama M, Sahin IH, Nooka A, Hassabo HM, Vauthey JN, Aloia T, Abbruzzese JL, Subbiah IM, Janku F, Curley S, Hassan MM. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology. 2013; 85(4):197-203. PMID: 24051705; PMCID: PMC3913463.
      Citations: 30     Fields:    Translation:Humans
    163. Kaseb AO. Beyond the basics: the differential effects of demographics and hepatitis status on treatment outcome in hepatocellular carcinoma. Oncology. 2013; 85(1):41-3. PMID: 23838536.
      Citations: 2     Fields:    Translation:Humans
    164. Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN. Modified cisplatin/interferon a-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer. 2013 Sep 15; 119(18):3334-42. PMID: 23821538; PMCID: PMC3775991.
      Citations: 9     Fields:    Translation:Humans
    165. Torres HA, Mahale P, Miller ED, Oo TH, Frenette C, Kaseb AO. Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World J Hepatol. 2013 Jun 27; 5(6):332-5. PMID: 23805358; PMCID: PMC3692975.
      Citations: 2     
    166. Hassan MM, Kaseb A, Etzel CJ, El-Serag H, Spitz MR, Chang P, Hale KS, Liu M, Rashid A, Shama M, Abbruzzese JL, Loyer EM, Kaur H, Hassabo HM, Vauthey JN, Wray CJ, Hassan BS, Patt YZ, Hawk E, Soliman KM, Li D. Genetic variation in the PNPLA3 gene and hepatocellular carcinoma in USA: risk and prognosis prediction. Mol Carcinog. 2013 Nov; 52 Suppl 1:E139-47. PMID: 23776098; PMCID: PMC3808509.
      Citations: 25     Fields:    Translation:Humans
    167. Frenette CT, Boktour M, Burroughs SG, Kaseb A, Aloia TA, Galati J, Gaber AO, Monsour H, Ghobrial RM. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation. Transpl Int. 2013 Jul; 26(7):734-9. PMID: 23701126.
      Citations: 5     Fields:    Translation:Humans
    168. Kaseb AO, Abaza YM, Roses RE. Multidisciplinary management of hepatocellular carcinoma. Recent Results Cancer Res. 2013; 190:247-59. PMID: 22941025.
      Citations: 4     Fields:    Translation:Humans
    169. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65. PMID: 23391555; PMCID: PMC3702215.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    170. Shindoh J, Kaseb A, Vauthey JN. Surgical strategy for liver cancers in the era of effective chemotherapy. Liver Cancer. 2013 Jan; 2(1):47-54. PMID: 24159596; PMCID: PMC3747536.
      Citations: 8     
    171. Das P, Abboud MT, Haque W, Javle M, Kaseb A, Curley SA, Vauthey JN, Aloia TA, Beddar AS, Delclos ME, Krishnan S, Crane CH. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Pract Radiat Oncol. 2013 Oct-Dec; 3(4):344-8. PMID: 24674408.
      Citations: 2     Fields:    
    172. Myers AL, Zhang YP, Kramer MA, Bornmann WG, Kaseb A, Yang P, Tran HT. A Practical Synthesis and X-ray Crystallographic Analysis of Dithymoquinone, a Photodimer of Thymoquinone. Lett Org Chem. 2012 Dec 01; 9(10):762-766. PMID: 24883052; PMCID: PMC4039186.
    173. Kim SM, Leem SH, Chu IS, Park YY, Kim SC, Kim SB, Park ES, Lim JY, Heo J, Kim YJ, Kim DG, Kaseb A, Park YN, Wang XW, Thorgeirsson SS, Lee JS. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology. 2012 May; 55(5):1443-52. PMID: 22105560; PMCID: PMC4060518.
      Citations: 65     Fields:    Translation:Humans
    174. Kaseb AO, Garrett-Mayer E, Morris JS, Xiao L, Lin E, Onicescu G, Hassan MM, Hassabo HM, Iwasaki M, Deaton FL, Abbruzzese JL, Thomas MB. Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial. Oncology. 2012; 82(2):67-74. PMID: 22327795.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    175. Mahale P, Kaseb A, Davila M, Torres HA. The effect of transcatheter arterial chemoembolization on hepatitis C viremia. Oncologist. 2012; 17(9):e21-3. PMID: 23002170; PMCID: PMC3448418.
      Citations:    Fields:    Translation:Humans
    176. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, Abdalla EK, Vauthey JN, Aloia TA, Krishnan S, Abbruzzese JL. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011 Oct 10; 29(29):3892-9. PMID: 21911725; PMCID: PMC3189091.
      Citations: 56     Fields:    Translation:Humans
    177. Kaseb AO, Abbruzzese JL, Vauthey JN, Aloia TA, Abdalla EK, Hassan MM, Lin E, Xiao L, El-Deeb AS, Rashid A, Morris JS. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology. 2011; 80(5-6):373-81. PMID: 21822028; PMCID: PMC3171278.
      Citations: 19     Fields:    Translation:Humans
    178. Skinner HD, Sharp HJ, Kaseb AO, Javle MM, Vauthey JN, Abdalla EK, Delclos ME, Das P, Crane CH, Krishnan S. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol. 2011 Nov; 50(8):1191-8. PMID: 21793641.
      Citations: 11     Fields:    Translation:Humans
    179. Kaseb AO, Hassan MM, Lin E, Xiao L, Kumar V, Pathak P, Lozano R, Rashid A, Abbruzzese JL, Morris JS. V-CLIP: Integrating plasma vascular endothelial growth factor into a new scoring system to stratify patients with advanced hepatocellular carcinoma for clinical trials. Cancer. 2011 Jun 01; 117(11):2478-88. PMID: 24048796; PMCID: PMC3066286.
      Citations: 22     Fields:    Translation:Humans
    180. Wilson SR, Greig P, Kaseb AO. Pretreatment assessment of hepatocellular cancer: expert consensus conference. HPB (Oxford). 2010 Jun; 12(5):300-1. PMID: 20590902; PMCID: PMC2951815.
      Citations: 6     Fields:    Translation:Humans
    181. Hassan MM, Curley SA, Li D, Kaseb A, Davila M, Abdalla EK, Javle M, Moghazy DM, Lozano RD, Abbruzzese JL, Vauthey JN. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010 Apr 15; 116(8):1938-46. PMID: 20166205; PMCID: PMC4123320.
      Citations: 117     Fields:    Translation:Humans
    182. El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9. PMID: 20107864.
      Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
    183. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer. 2009 Nov 01; 115(21):4895-906. PMID: 19637355.
      Citations: 41     Fields:    Translation:Humans
    184. Banerjee S, Kaseb AO, Wang Z, Kong D, Mohammad M, Padhye S, Sarkar FH, Mohammad RM. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer. Cancer Res. 2009 Jul 01; 69(13):5575-83. PMID: 19549912.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    185. Hassan MM, Kaseb A, Li D, Patt YZ, Vauthey JN, Thomas MB, Curley SA, Spitz MR, Sherman SI, Abdalla EK, Davila M, Lozano RD, Hassan DM, Chan W, Brown TD, Abbruzzese JL. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. Hepatology. 2009 May; 49(5):1563-70. PMID: 19399911; PMCID: PMC3715879.
      Citations: 56     Fields:    Translation:Humans
    186. Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO, Curley SA, Abdalla EK, Vauthey JN. Major hepatic resection for hepatocellular carcinoma with or without portal vein embolization: Perioperative outcome and survival. Surgery. 2009 Apr; 145(4):399-405. PMID: 19303988.
      Citations: 34     Fields:    Translation:Humans
    187. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009 Feb 20; 27(6):843-50. PMID: 19139433.
      Citations: 115     Fields:    Translation:HumansCTClinical Trials
    188. Hassan MM, Spitz MR, Thomas MB, Curley SA, Patt YZ, Vauthey JN, Glover KY, Kaseb A, Lozano RD, El-Deeb AS, Nguyen NT, Wei SH, Chan W, Abbruzzese JL, Li D. The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States. J Hepatol. 2009 Feb; 50(2):334-41. PMID: 19070394; PMCID: PMC2658718.
      Citations: 35     Fields:    Translation:Humans
    189. Hassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, Chan W, Kaseb A, Curley SA, Vauthey JN, Ellis LM, Abdalla E, Lozano RD, Patt YZ, Brown TD, Abbruzzese JL, Li D. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer. 2008 Oct 15; 123(8):1883-91. PMID: 18688864; PMCID: PMC2673571.
      Citations: 29     Fields:    Translation:HumansPHPublic Health
    190. Kaseb AO, Chinnakannu K, Chen D, Sivanandam A, Tejwani S, Menon M, Dou QP, Reddy GP. Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 2007 Aug 15; 67(16):7782-8. PMID: 17699783.
      Citations: 67     Fields:    Translation:HumansAnimalsCells
    191. Bai VU, Kaseb A, Tejwani S, Divine GW, Barrack ER, Menon M, Pardee AB, Reddy GP. Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc Natl Acad Sci U S A. 2007 Feb 13; 104(7):2343-8. PMID: 17283334; PMCID: PMC1892964.
      Citations: 11     Fields:    Translation:Humans
    192. Personalized medicine and targeted therapy of hepatocellular carcinoma. 765-779.
    193. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 7:69916-69926.
    194. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals. Journal of Hepatology. 65:862-864.
    195. Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with increasing DNA promoter methylation. Asian Pacific Journal of Cancer Prevention. 14:6721-6726.
    196. Second-line systemic treatment for advanced cholangiocarcinoma. Journal of Gastrointestinal Oncology. 5:408-413.
    197. Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma. Oncotarget. 6:21193-21207.
    198. Type I insulin-like growth factor receptor signaling in hematological malignancies. Oncotarget. 8:1814-1844.
    199. Inactivation of hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma. Clinical Cancer Research. 22:1256-1264.
    200. Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs. Oncology (Switzerland). 90-100.
    201. Transarterial hepatic chemoembolization with 70-150 μm drug-eluting beads. Journal of Vascular and Interventional Radiology. 26:965-971.
    202. Kalonji (Thymoquinone). 257-280.
    203. Reply to A. Goyal et al. Journal of Clinical Oncology. 30:1019-1020.
    204. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 7:67521-67531.
    205. A practical synthesis and X-ray crystallographic analysis of dithymoquinone, a photodimer of thymoquinone. Letters in Organic Chemistry. 9:762-766.
    206. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK<sup>+</sup> T-cell lymphoma. Molecular Cancer. 14.
    207. Epidemiology and pathogenesis of hepatocellular carcinoma. 1-19.
    208. Biliary cancer. Cancer.
    209. Gastric bleeding after radiation therapy for intrahepatic cholangiocarcinoma. Practical Radiation Oncology. 3:344-348.
    210. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma. Oncotarget. 6:28453-28462.
    211. Targets by organ site.
    212. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. Cancer.
    213. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Alimentary Pharmacology and Therapeutics. 44:1235-1241.
    214. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma. Journal of Clinical Oncology. 34:219-226.
    215. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. Journal of the National Cancer Institute. 106.
    216. Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery. 1-7.
    217. Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers. European Journal of Nuclear Medicine and Molecular Imaging. 1-10.
    218. Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment. OncoTargets and Therapy. 7:1927-1932.
    219. HER2/neu-directed therapy for biliary tract cancer. Journal of Hematology and Oncology. 8.
    220. The future. 369-382.
    221. Targets by organ site.
    222. Multimodal approach and long-term survival in a patient with recurrent metastatic acinar cell carcinoma of the pancreas. Pancreatology. 16:153-156.
    223. Liver cancer. 95-119.
    224. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. OncoTargets and Therapy. 9:773-780.
    KASEB's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (407)
    Co-Authors (166)
    Similar People (60)
    Same Department Expand Description